Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Humans
Child
Infant
Child, Preschool
Adolescent
Burkitt Lymphoma
/ therapy
Organ Transplantation
/ adverse effects
Cyclophosphamide
/ therapeutic use
Rituximab
/ therapeutic use
Prednisone
/ therapeutic use
Lymphoproliferative Disorders
/ etiology
Treatment Outcome
Retrospective Studies
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Burkitt lymphoma
lymphoproliferative disorder
post-solid-organ transplantation
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
08
09
2022
received:
08
07
2022
accepted:
21
09
2022
pubmed:
2
12
2022
medline:
21
1
2023
entrez:
1
12
2022
Statut:
ppublish
Résumé
Burkitt lymphoma arising in paediatric post-solid-organ transplantation-Burkitt lymphoma (PSOT-BL) is a clinically aggressive malignancy and a rare form of post-transplant lymphoproliferative disorder (PTLD). We evaluated 35 patients diagnosed with PSOT-BL at 14 paediatric medical centres in the United States. Median age at organ transplantation was 2.0 years (range: 0.1-14) and age at PSOT-BL diagnosis was 8.0 years (range: 1-17). All but one patient had late onset of PSOT-BL (≥2 years post-transplant), with a median interval from transplant to PSOT-BL diagnosis of 4.0 years (range: 0.4-12). Heart (n = 18 [51.4%]) and liver (n = 13 [37.1%]) were the most frequently transplanted organs. No patients had loss of graft or treatment-related mortality. A variety of treatment regimens were used, led by intensive Burkitt lymphoma-specific French-American-British/Lymphomes Malins B (FAB/LMB), n = 13 (37.1%), and a low-intensity regimen consisting of cyclophosphamide, prednisone and rituximab (CPR) n = 12 (34.3%). Median follow-up was 6.7 years (range: 0.5-17). Three-year event-free and overall survival were 66.2% and 88.0%, respectively. Outcomes of PSOT-BL patients receiving BL-specific intensive regimens are comparable to reported BL outcomes in immunocompetent children. Multi-institutional collaboration is feasible and provides the basis of prospective data collection to determine the optimal treatment regimen for PSOT-BL.
Substances chimiques
Cyclophosphamide
8N3DW7272P
Rituximab
4F4X42SYQ6
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
297-305Informations de copyright
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
Références
Mbulaiteye SM, Clarke CA, Morton LM, Gibson TM, Pawlish K, Weisenburger DD, et al. Burkitt lymphoma risk in U.S. solid organ transplant recipients. Am J Hematol. 2013;88(4):245-50. https://doi.org/10.1002/ajh.23385
Yanik EL, Shiels MS, Smith JM, Clarke CA, Lynch CF, Kahn AR, et al. Contribution of solid organ transplant recipients to the pediatric non-Hodgkin lymphoma burden in the United States. Cancer. 2017;123(23):4663-71. https://doi.org/10.1002/cncr.30923
Bobillo S, Abrisqueta P, Sánchez-González B, Giné E, Romero S, Alcoceba M, et al. Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series. Ann Hematol. 2018;97(12):2417-24. https://doi.org/10.1007/s00277-018-3473-8
Zimmermann H, Reinke P, Neuhaus R, Lehmkuhl H, Oertel S, Atta J, et al. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients. Cancer. 2012;118(19):4715-24. https://doi.org/10.1002/cncr.27482
Gong JZ, Stenzel TT, Bennett ER, Lagoo AS, Dunphy CH, Moore JO, et al. Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. Am J Surg Pathol. 2003;27(6):818-27. https://doi.org/10.1097/00000478-200306000-00014
Egan G, Weitzman S, Burkitt AS. Lymphoma and diffuse large B-cell lymphoma. In: Abla O, Attarbaschi A, editors. Non-Hodgkin's lymphoma in childhood and adolescence. 1st ed. Switzerland: Springer Nature; 2019. p. 167-183l. https://doi.org/10.1007/978-3-030-11769-6
Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30(4):387-93. https://doi.org/10.1200/JCO.2010.33.3369
Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736-43. https://doi.org/10.1182/blood-2006-07-036665
Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773-80. https://doi.org/10.1182/blood-2006-07-036673
Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood. 2005;105(3):948-58. https://doi.org/10.1182/blood-2004-03-0973
Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children. N Engl J Med. 2020;382(23):2207-19. https://doi.org/10.1056/NEJMoa1915315
Afify Z, Punnett A. Post solid organ transplant Burkitt lymphoma. In: Berthelot DV, editor. Burkitt lymphoma: diagnosis, risk factors and treatment. New York: Nova; 2021. p. 143-78. https://doi.org/10.52305/VODC3429
Maecker-Kolhoff B, Beier R, Zimmermann M, Schlegelberger B, Baumann U, Mueller C, et al. Response-adapted sequential Immuno-chemotherapy of post-transplant lymphoproliferative disorders in pediatric solid organ transplant recipients: results from the prospective ped-PTLD 2005 trial. [abstract] Blood 2014;124:4468. Abstract 624. https://doi.org/10.1182/blood.V124.21.4468.4468
Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017;35(5):536-43. https://doi.org/10.1200/JCO.2016.69.3564
Zimmermann H, Xu H, Barlev AA, Feng A, Li X, Navarro W, Trappe R, et al. Clinical outcomes of solid organ transplant patients with EBV+PTLD who fail first-line rituximab or rituximab plus chemotherapy: an analysis of German PTLD registry [Abstract]. Eur Hematol Assoc. 2019;3(S1):3148. Abstract PF719. https://library.ehaweb.org/eha/2019/24th/266518/heiner.zimmermann.clinical.outcomes.of.solid.organ.transplant.patients.with.html
Kanzelmeyer NK, Maecker-Kolhoff B, Zierhut H, Lerch C, Verboom M, Haffner D, et al. Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study. Transpl Int. 2018;31(4):367-76. https://doi.org/10.1111/tri.13071
Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13(2):196-206. https://doi.org/10.1016/S1470-2045(11)70300-X
Picarsic J, Jaffe R, Mazariegos G, Webber SA, Ellis D, Green MD, et al. Post-transplant Burkitt lymphoma is a more aggressive and distinct form of post-transplant lymphoproliferative disorder. Cancer. 2011;117(19):4540-50. https://doi.org/10.1002/cncr.26001
AbdelHameid D, Felice A, Cooper LB, Katugaha SB. Long-term remission in an adult heart transplant recipient with advanced Burkitt's lymphoma post-transplant lymphoproliferative disorder after anthracycline-free chemotherapy: a case report and literature review. Transpl Infect Dis. 2020;22(4):e13265. https://doi.org/10.1111/tid.13265
El-Atoum B, Williams M, Molina K, Orjuela-Grimm MA, Prince J, Afify Z. Burkitt lymphoma after cardiac transplantation: therapeutic considerations. J Pediatr Hematol Oncol. 2022;44(3):100-2. https://doi.org/10.1097/MPH.0000000000002260
Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's oncology group report. Am J Transplant. 2012;12(11):3069-75. https://doi.org/10.1111/j.1600-6143.2012.04206.x
Leoncini L, Campo E, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe HS, Pileri SA, Stein H, Theile J, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2017. p. 330-4.
Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332-9.
Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, et al. Revised international pediatric non-Hodgkin lymphoma staging system. J Clin Oncol. 2015;33(18):2112-8. https://doi.org/10.1200/JCO.2014.59.7203
Orjuela MA, Alobeid B, Liu X, Siebert AL, Kott ER, Addonizio LJ, et al. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. Br J Haematol. 2011;152(6):733-42. https://doi.org/10.1111/j.1365-2141.2010.08448.x
Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res. 2003;9(10 Pt 2):3945S-52S.
Rubinstein JD, Shah R, Breese EH, Burns KC, Mangino JL, Norris RE, et al. Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: short-course EPOCH regimens are safe and effective. Pediatr Blood Cancer 2021;68(8):e29126. https://doi.org/10.1002/pbc.29126
Cohen-Gogo S, Landman-Parker GJ, Michel H, Pacquement H, Michon J, Bertrand Y, et al. LMB chemotherapy is effective for Burkitt lymphoma occurring after sold organ transplantation in children: a report from the societe francaise des cancers de L'enfante (SFCE). [abstract]. Pediatr Blood Cancer. 2019;66(Suppl):S260. Abstract 197.4. https://doi.org/10.1002/pbc.27989
Windebank K, Walwyn T, Kirk R, Parry G, Hasan A, Bown N, et al. Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab. Pediatr Blood Cancer. 2009;53(3):392-6. https://doi.org/10.1002/pbc.22070
Thacker N, Abla O. Epidemiology of non-Hodgkin lymphomas in childhood and adolescence. In: Abla O, Attarbaschi A, editors. Non-Hodgkin's lymphoma in childhood and adolescenc. Cham: Springer; 2019. p. 15-22. https://doi.org/10.1007/978-3-030-11769-6_2
Ferreiro JF, Morscio J, Dierickx D, Marcelis L, Verhoef G, Vandenberghe P, et al. Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern. Haematologica. 2015;100(7):e275-9. https://doi.org/10.3324/haematol.2015.124305
Rituximab and LMP-specific T-cells in treating pediatric solid organ recipients with EBV-positive, CD20-positive post-transplant lymphoproliferative disorder. https://clinicaltrials.gov/ct2/show/NCT02900976. Last updated April 30, 2021. Accessed May 4, 2022.
Schober T, Framke T, Kreipe H, Schulz TF, Grohennig A, Hussein K, et al. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation. 2013;95(1):240-6. https://doi.org/10.1097/TP.0b013e318277e344
Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.Blood 2010;115(15):3017-24.19.
Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369(20):1915-25. https://doi.org/10.1056/NEJMoa1308392
Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol. 2020;38(22):2519-29. https://doi.org/10.1200/JCO.20.00303
Iglesias Cardenas F, Agarwal AM, Vagher J, Maese L, Fluchel M, Afify Z. Two clonally distinct B-cell lymphomas reveal the diagnosis of XLP1 in a male child and his asymptomatic male relatives: case report and review of the literature. J Pediatr Hematol Oncol. 2021;43(8):e1210-3. https://doi.org/10.1097/MPH.0000000000002049
Zhou D, Paxton CN, Kelley TW, Afify Z, South ST, Miles RR. Two unrelated Burkitt lymphomas seven years apart in a patient with X-linked lymphoproliferative disease type 1 (XLP1). Am J Clin Pathol. 2016;146(2):248-53. https://doi.org/10.1093/ajcp/aqw036
Afify Z, Abla O. Reducing treatment burden matters in special populations with pediatric B-non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2021;43(8):e1270. https://doi.org/10.1097/MPH.0000000000002335
Afify Z, Abla O. Burkitt lymphoma in patients with primary immune deficiency disorders. In: Berthelot DV, editor. Burkitt lymphoma: diagnosis, risk factors and treatment. Hauppauge, New York: Nova Publishers; 2021. p. 89-142. https://doi.org/10.52305/VODC3429
Dalal M, Liu C, Drew K, Slayton W, Shih R, Collins W, et al. Concurrent subtypes of post-transplant lymphoproliferative disorders after solid organ transplant. [abstract] Pediatr Blood Cancer 2021;68(Suppl):S186. https://doi.org/10.1002/pbc.29060
Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141(6):840-7. https://doi.org/10.1111/j.1365-2141.2008.07144.x
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdullah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-42. https://doi.org/10.1056/NEJMoa011795
Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a pediatric oncology group phase III trial. J Clin Oncol. 2005;23(3):541-7. https://doi.org/10.1200/JCO.2005.11.075